Eli Lilly scores a first in major pharma milestone

Eli Lilly (LLY) just did something worth paying attention to.

With CVS Caremark announcing coverage of both Zepbound and newly approved Foundayo starting this summer, all three of the largest U.S. pharmacy benefit managers now cover Lilly’s complete obesity medicine portfolio.

That’s a clean sweep of Express Scripts, Optum Rx, and CVS Caremark combined, covering hundreds of millions of Americans.

Pharmacy benefit managers, commonly called PBMs, are the companies that decide which drugs get covered on insurance plans, what patients pay out of pocket, and ultimately which products get used.

Getting one of the big three on your side is a win. Getting all three for your entire portfolio, across both an injectable and a first-of-its-kind oral GLP-1 medication, is without precedent.

The timing matters, too. Lilly’s first-quarter 2026 earnings already showed the company firing on every cylinder.

Revenue hit $19.80 billion, up 55.5% year over year, and management raised its full-year revenue guidance to between $82 billion and $85 billion, according to Eli Lilly’s official Q1 2026 earnings report.

The CVS development now hands the company a fresh growth lever heading into the second half.

What CVS Caremark’s reversal actually means for Lilly

CVS Caremark had previously dropped Zepbound from its preferred formulary (approved drug list) in July 2025, striking a deal that gave rival Novo Nordisk’s Wegovy exclusive preferred status, according to Mass.gov.

That decision triggered a class-action lawsuit from Zepbound patients who disputed the claim that the two drugs were interchangeable, Fierce Pharma reported.

The reversal changes the entire competitive equation.

More Eli Lilly:

Morgan Stanley flags vital Eli Lilly signal for 2026BofA sees more upside in Eli Lilly stockEli Lilly stock swings after FDA liver failure report for GLP-1 drug

Starting June 1, CVS Caremark began covering Foundayo, Lilly’s once-daily oral obesity pill and currently the only such drug approved without restrictions on food or water intake.

Zepbound returns as a co-preferred option on October 1, joining Wegovy on the same tier.

The CVS formulary template covers approximately 25 to 30 million Americans, The Boston Globe confirmed, making this a direct unlock of new patient volume.

CVS Caremark President Ed DeVaney confirmed in a press release that the PBM negotiated meaningful savings in the process, estimating 10% to 15% additional cost reductions across the weight management category for its clients.

Eli Lilly has locked in full coverage across all three major U.S. pharmacy benefit managers for its obesity medicine portfolio.

jetcityimage / Getty Images

The bull case signal Wall Street may be underestimating

Lilly entered 2026 holding a 60.1% share of the combined U.S. obesity and diabetes GLP-1 drug market in Q1, according to CNBC’s earnings coverage.

Novo Nordisk’s (NVO) share stood at 39.4% in the same period.

The CVS reinstatement now eliminates the one market-access gap Novo had over Lilly, removing a structural advantage that had forced some patients to switch drugs against their preference.

Here is what the bull case now requires to hold:

Zepbound and Foundayo volume accelerating through October 1, when full CVS coverage activates for the injectableRealized pricing stabilizing, after Zepbound’s U.S. realized prices fell 13% in Q1 despite volume rising 80% over the same period in 2025Foundayo uptake continuing, with the new oral pill already reaching 20,000 patients in its first weeks of launch, with 80% representing new-to-class users

That third point is particularly important. New-to-class users represent untapped demand, not just patients switching from existing drugs.

Foundayo’s oral format removes one of the biggest historical barriers to GLP-1 adoption: the reluctance to self-inject.

Cantor Fitzgerald lifted its LLY price target to $1,230 with an Overweight rating after Q1, citing Mounjaro demand and Foundayo momentum, according to Yahoo Finance.

The consensus across 31 analysts polled by S&P Global currently sits at a Buy rating with an average price target of $1,215, Stock Analysis data shows.

What still needs to happen before H2 revenue shifts

Full CVS coverage does not guarantee every plan sponsor adopts it.

Employers and health plans that use CVS Caremark formularies can still opt out of covering GLP-1s for weight loss, NBC News noted.

That means October 1 activates the opportunity, not the guaranteed revenue.

Lilly’s own guidance already reflects this uncertainty.

The company projects full-year 2026 revenue between $82 billion and $85 billion, having raised that range by $2 billion after Q1.

How much of the CVS expansion flows into H2 numbers will depend on how quickly plan sponsors adopt the updated formulary.

Related: Banking giant massively resets Jazz Pharma stock price target

Analysts tracking the GLP-1 space will closely watch two things: whether Zepbound’s U.S. pricing stabilizes and if Foundayo’s rapid early uptake sustains through the second and third quarters.

A pricing floor, combined with accelerating Foundayo enrollment, would give Lilly room to exceed even its raised guidance.

The Medicare side adds another layer.

Eligible Medicare Part D beneficiaries can pay $50 monthly for Lilly’s obesity medications starting July 1 through the Medicare GLP-1 Bridge program, which Lilly confirmed in a company statement.

LLY vs. the S&P 500: the scorecard

Lilly’s stock jumped approximately 5% on the day of the CVS announcement, according to TipRanks data. For context, here is how LLY has tracked against the broader market:

1 month: LLY up significantly after Q1 earnings; S&P 500 recovering from April volatility.Year to date: LLY down approximately 9% from its 52-week high of $1,132, with the stock trading near $1,064 before the CVS news.1 year: LLY up about 45%, compared to the S&P 500’s 28% return over the same window.5 years: LLY up more than 450%, versus the S&P 500’s approximately 80% return over the same period.
Source: Alpha Spread

The CVS news arrives as Lilly trades below its 52-week high, giving investors a setup where the stock has room to recover toward analyst targets if H2 revenue performs as the CVS access expansion suggests it should.

The bottom line for LLY investors

Eli Lilly has just completed a commercial milestone that puts Lilly and Novo Nordisk on equal formulary footing for the first time:

Lilly’s full portfolio coverage across all three major U.S. PBMs unlocks an estimated 25-30 million additional potential patients through the CVS network alone.

The near-term risk remains pricing pressure on Zepbound, which has seen realized prices fall even as volume climbs.

Investors comfortable with that trade-off and confident in Foundayo’s new-to-class user adoption are looking at a stock trading below analyst consensus, with a new tailwind entering the second half of 2026.

Those who want more certainty should watch October 1, when CVS Caremark’s Zepbound coverage fully activates across standard commercial template plans, as the real litmus test for how much H2 revenue this milestone can actually deliver.

Related: 245-year-old pharma giant cuts 4,500 jobs amid legal troubles

#Eli #Lilly #scores #major #pharma #milestone